David Venables PhD

Dr David Venables is CEO of Synpromics Ltd, and recently completed two successful fund raising rounds of £7.5M in total. He has previously served as VP CMC for NightstaRx, an ophthalmology focused gene therapy company; CEO of Anatara Therapeutics (a life sciences company managed through to IPO in Australia); CEO of Ark Therapeutics, leading the company through a business transition and sale as a gene therapy CDMO. Previously at Intercell, he was responsible for building Intercell’s manufacturing capabilities in Europe and the USA. Initially as Site Head for vaccine manufacturing operations in the UK followed by Chief Operating Officer of Intercell USA Inc. based in Maryland, USA.